2025 Year in Review: Looking Ahead to Psychedelics in 2026 (Video) - Psychedelic Alpha

Psychedelic Alpha Founder and Editor Josh Hardman lays out what could drive psychedelics progress in 2026. The narrated slide deck focuses on likely FDA approvals and upcoming late stage milestones, including potential Phase 3 readouts. It also discusses alternative pathways for gaining access beyond standard clinical routes, positioning regulatory movement, trial outcomes, and access mechanisms as key themes for what the year ahead may bring.